When and How Can Endpoints Be Changed after Initiation of a Randomized Clinical Trial

This publication has 9 references indexed in Scilit:

• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  Published by Elsevier ,2005
• Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
  CMAJ : Canadian Medical Association Journal, 2004
• The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive)
  Diabetes Care, 2004
• Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials
  JAMA, 2004
• On changing a long‐term clinical trial midstream
  Statistics in Medicine, 2002
• Journals should see original protocols for clinical trials
  BMJ, 2001
• The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts
  New England Journal of Medicine, 1997
• Issues in the early termination of the aspirin component of the physicians' health study
  Annals of Epidemiology, 1991
• The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction.
  1988